Soluble thyroid tumor markers - old and new challenges and potential solutions

New Zealand Journal of Medical Laboratory Science

Volumn 67, Issue 3, 2013, Pages 76-87

  Grebe, Stefan K G ^a  

^a MAYO CLINIC ROCHESTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PENDRIN; SODIUM IODIDE SYMPORTER; THYROGLOBULIN; TUMOR MARKER;

ARTICLE; CIRCULATING TUMOR CELL; DIFFERENTIATED THYROID CANCER; FOLLOW UP; HUMAN; IMMUNOASSAY; THYROID TUMOR;

EID: 84898605515     PISSN: 11710195     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (102)

1. Pellegriti G, Frasca F, Regalbuto C, Squatrito S, Vigneri R. Worldwide increasing incidence of thyroid cancer: update on epidemiology and risk factors. J Cancer Epidemiol 2013; 2013: 965212.
2. Albores-Saavedra J, Henson DE, Glazer E, Schwartz AM. Changing patterns in the incidence and survival of thyroid cancer with follicular phenotype--papillary, follicular, and anaplastic: a morphological and epidemiological study. Endocr Pathol 2007; 18: 1-7.
3. Aschebrook-Kilfoy B, Kaplan EL, Chiu BC, Angelos P, Grogan RH. The acceleration in papillary thyroid cancer incidence rates is similar among racial and ethnic groups in the United States. Ann Surg Oncol 2013; 20: 2746-2753.
4. Eszlinger M, Krohn K, Hauptmann S, Dralle H, Giordano TG, Paschke R. Perspectives for improved and more accurate classification of thyroid epithelial tumors. J Clin Endocrinol Metab 2008; 93: 3286-3294.
5. Aschebrook-Kilfoy B, Ward MH, Sabra MM, Devesa SS. Thyroid cancer incidence patterns in the United States by histologic type, 1992-2006. Thyroid 2011; 21: 125-134.
6. Figge J. Epidemiology of thyroid cancer. In: L Wartofsky, D Nostrand, editors. Thyroid Cancer. Humana Press, New York, 2006: 9-13.
7. Kovacs GL, Gonda G, Vadasz G, Ludmany E, Uhrin K, Gorombey Z, et al. Epidemiology of thyroid microcarcinoma found in autopsy series conducted in areas of different iodine intake. Thyroid 2005; 15: 152-157.
8. Leung AM, Dave S, Lee SL, Campion FX, Garber JR, Pearce EN. Factors determining the persistence or recurrence of well-differentiated thyroid cancer treated by thyroidectomy and/or radioiodine in the Boston, Massachusetts area: A retrospective chart review. Thyroid Res 2011; 4: 9.
9. Grebe SK, Hay ID. Thyroid cancer nodal metastases: biologic significance and therapeutic considerations. Surg Oncol Clin N Am 1996; 5: 43-63.
10. Deshpande V, Venkatesh SG. Thyroglobulin, the prothyroid hormone: chemistry, synthesis and degradation. Biochim BiophysActa 1999; 1430: 157-178.
11. Berndorfer U, Wilms H, Herzog V. Multimerization of thyroglobulin (TG) during extracellular storage: isolation of highly cross-linked TG from human thyroids. J Clin Endocrinol Metab 1996; 81: 1918-1926.
12. Giovanella L, Imperiali M, Ferrari A, Palumbo A, Furlani L, Graziani MS, et al. Serum thyroglobulin reference values according to NACB criteria in healthy subjects with normal thyroid ultrasound. Clin Chem Lab Med 2012; 50: 891-893.
13. Unger J, De Maertelaer V, Golstein J, Decoster C, Jonckheer MH. Relationship between serum thyroglobulin and intrathyroidal stable iodine in human simple goitre. Clin Endocrinol (Oxf) 1985; 23: 1-6.
14. Baloch Z, Carayon P, Conte-Devolx B, Demers LM, Feldt-Rasmussen U, Henry JF, et al. Laboratory medicine practice guidelines. Laboratory support for the diagnosis and monitoring of thyroid disease. Thyroid 2003; 13: 3-126.
15. Grebe SK. Diagnosis and management of thyroid carcinoma: a focus on serum thyroglobulin. Expert Rev Endocrinol Metab 2008; 4: 25-43.
16. Feldt-Rasmussen U, Petersen PH, Date J, Madsen CM. Serum thyroglobulin in patients undergoing subtotal thyroidectomy for toxic and nontoxic goiter. J Endocrinol Invest 1982; 5: 161-164.
17. Feldt-Rasmussen U, Petersen PH, Nielsen H, Date J, Madsen CM. Thyroglobulin of varying molecular sizes with different disappearance rates in plasma following subtotal thyroidectomy. Clin Endocrinol (Oxf) 1978; 9: 205-214.
18. Giovanella L, Ceriani L, Maffioli M. Postsurgery serum thyroglobulin disappearance kinetic in patients with differentiated thyroid carcinoma. Head Neck 2010; 32: 568571.
19. Hocevar M, Auersperg M, Stanovnik L. The dynamics of serum thyroglobulin elimination from the body after thyroid surgery. Eur J Surg Oncol 1997; 23: 208-210.
20. Izumi M, Kubo I, Taura M, Yamashita S, Morimoto I, Ohtakara S, et al. Kinetic study of immunoreactive human thyroglobulin. J Clin Endocrinol Metab 1986; 62: 410-412.
21. American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, et al. 2009 Revised American Thyroid Association Management Guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009; 19: 1167-1214.
22. Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JW, Wiersinga W, et al. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol 2006; 154: 787-803. Erratum in Eur J Endocrinol 2006; 155: 385.
23. Shammas A, Degirmenci B, Mountz JM, McCook BM, Branstetter B, Bencherif B, et al. 18F-FDG PET/CT in patients with suspected recurrent or metastatic well-differentiated thyroid cancer. J Nucl Med 2007; 48: 221-226. Erratum in J Nucl Med 2007; 48: 412.
24. Tuttle RM, Ball DW, Byrd D, Dickson P, Duh QY, Farrar WB, et al. NCCN Clinical Practice Guidelines in Oncology -Thyroid Carcinoma - Version 2.2013. In: NCCN Guidelines, 2013.
25. Toubeau M, Touzery C, Arveux P, Chaplain G, Vaillant G, Berriolo A, et al. Predictive value for disease progression of serum thyroglobulin levels measured in the postoperative period and after 131 i ablation therapy in patients with differentiated thyroid cancer. J Nucl Med 2004; 45: 988-994.
26. Schlumberger M, Baudin E. Serum thyroglobulin determination in the follow-up of patients with differentiated thyroid carcinoma. EurJ Endocrinol 1998; 138: 249-252.
27. Aras G, Gultekin SS, Kuguk NO, Geng Y. Is thyroglobulin the stronger indicator for progressive disease than the other conventional factors in same age patient groups with differentiated thyroid cancer? Nucl Med Commun 2007; 28: 907-913.
28. Pacini F, Castagna MG, Brilli L, Pentheroudakis G, ESMO Guidelines Working Group. Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010; 21 Suppl 5: v214-v219.
29. Shigematsu N, Takami H, Ito N, Kubo A. Nationwide survey on the treatment policy for well-differentiated thyroid cancer -results of a questionnaire distributed at the 37th Meeting of the Japanese Society of Thyroid Surgery. Endocr J 2005; 52: 479-491.
30. Shigematsu N, Takami H, Kubo A. Unique treatment policy for well-differentiated thyroid cancer in Japan: results of a questionnaire distributed to members of the Japanese Society of Thyroid Surgery and the International Association of Endocrine Surgeons. Endocr J 2006; 53: 829-839.
31. Spencer CA. Clinical review: Clinical utility of thyroglobulin antibody (TgAb) measurements for patients with differentiated thyroid cancers (DTC). J Clin Endocrinol Metab 2011; 96: 3615-3627.
32. Spencer C, Petrovic I, Fatemi S. Current thyroglobulin autoantibody (TgAb) assays often fail to detect interfering TgAb that can result in the reporting of falsely low/undetectable serum Tg IMA values for patients with differentiated thyroid cancer. J Clin Endocrinol Metab 2011; 96: 1283-1291.
33. Preissner CM, O'Kane DJ, Singh RJ, Morris JC, Grebe SK. Phantoms in the assay tube: heterophile antibody interferences in serum thyroglobulin Assays. J Clin Endocrinol Metab 2003; 88: 3069-3074.
34. Algeciras-Schimnich A, Lasho MA, Ness KM, Cheryk LA, Grebe SK. The Roche Elecsys and Siemens-Centaur thyroglobulin autoantibody assays show comparable clinical performance to the recently unavailable Beckman-Coulter access thyroglobulin autoantibody assay in identifying samples with potentially false-low thyroglobulin measurements due to thyroglobulin autoantibody interference. Thyroid 2011; 21: 813-814.
35. Ditkoff BA, Marvin MR, Yemul S, Shi YJ, Chabot J, Feind C, et al. Detection of circulating thyroid cells in peripheral blood. Surgery 1996; 120:959-964; discussion 964-965.
36. Ringel MD, Ladenson PW, Levine MA. Molecular diagnosis of residual and recurrent thyroid cancer by amplification of thyroglobulin messenger ribonucleic acid in peripheral blood. J Clin Endocrinol Metab 1998; 83: 4435-4442.
37. Tallini G, Ghossein RA, Emanuel J, Gill J, Kinder B, Dimich AB, et al. Detection of thyroglobulin, thyroid peroxidase, and RET/PTC1 mRNA transcripts in the peripheral blood of patients with thyroid disease. J Clin Oncol 1998; 16: 1158-1166.
38. Ringel MD, Balducci-Silano PL, Anderson JS, Spencer CA, Silverman J, Sparling YH, et al. Quantitative reverse transcription-polymerase chain reaction of circulating thyroglobulin messenger ribonucleic acid for monitoring patients with thyroid carcinoma. J Clin Endocrinol Metab 1999; 84: 4037-4042.
39. Wingo ST, Ringel MD, Anderson JS, Patel AD, Lukes YD, Djuh YY, et a. 1999 Quantitative reverse transcription-PCR measurement of thyroglobulin mRNA in peripheral blood of healthy subjects. Clin Chem 1999; 45: 785-789.
40. Biscolla RP, Cerutti JM, Maciel RM. Detection of recurrent thyroid cancer by sensitive nested reverse transcription-polymerase chain reaction of thyroglobulin and sodium/iodide symporter messenger ribonucleic acid transcripts in peripheral blood. J Clin Endocrinol Metab 2000; 85: 3623-3627.
41. Bojunga J, Roddiger S, Stanisch M, Kusterer K, Kurek R, Renneberg H, et al. Molecular detection of thyroglobulin mRNA transcripts in peripheral blood of patients with thyroid disease by RT-PCR. Br J Cancer2000; 82: 1650-1655.
42. Bellantone R, Lombardi CP, Bossola M, Ferrante A, Princi P, Boscherini M, et al. Validity of thyroglobulin mRNA assay in peripheral blood of postoperative thyroid carcinoma patients in predicting tumor recurrences varies according to the histologic type: results of a prospective study. Cancer 2001; 92: 2273-2279.
43. Fenton C, Anderson JS, Patel AD, Lukes Y, Solomon B, Tuttle RM, et al. Thyroglobulin messenger ribonucleic acid levels in the peripheral blood of children with benign and malignant thyroid disease. Pediatr Res 2001; 49: 429-434.
44. Takano T, Miyauchi A, Yoshida H, Hasegawa Y, Kuma K, Amino N. Quantitative measurement of thyroglobulin mRNA in peripheral blood of patients after total thyroidectomy. Br J Cancer 2001; 85: 102-106.
45. Eszlinger M, Neumann S, Otto L, Paschke R. Thyroglobulin mRNA quantification in the peripheral blood is not a reliable marker for the follow-up of patients with differentiated thyroid cancer. Eur J Endocrinol 2002; 147: 575-582.
46. Fugazzola L, Mihalich A, Persani L, Cerutti N, Reina M, Bonomi M, et al. Highly sensitive serum thyroglobulin and circulating thyroglobulin mRNA evaluations in the management of patients with differentiated thyroid cancer in apparent remission. J Clin Endocrinol Metab 2002; 87: 3201-3208.
47. Savagner F, Rodien P, Reynier P, Rohmer V, Bigorgne JC, Malthiery Y. Analysis of Tg transcripts by real-time RT-PCR in the blood of thyroid cancer patients. J Clin Endocrinol Metab 2002; 87: 635-639.
48. Deniot A, Delfino C, Dutour-Meyer A, Fina F, Ouafik LH. Evaluation of quantitative measurement of thyroglobulin mRNA in the follow-up of differentiated thyroid cancer. Thyroid 2003 13: 867-872.
49. Grammatopoulos D, Elliott Y, Smith SC, Brown I, Grieve RJ, Hillhouse EW, et al. Measurement of thyroglobulin mR A in peripheral blood as an ad unctive test for monitoring thyroid cancer. Mol Pathol 2003 6: 162-166.
50. Span PN, Sleegers MJM, van den Broek WJ, Ross HA, Nieuwlaat WA, Hermus AR et al. Quantitative detection of peripheral thyroglobulin mR A has limited clinical value in the follow-up of thyroid cancer patients. Ann Clin Biochem 2003 40: 94-99.
51. Barzon L, Boscaro M, Pacenti M, Taccaliti A, Palu G. Evaluation of circulating thyroid-specific transcripts as markers of thyroid cancer relapse. Int J Cancer 2004 110: 914-920.
52. Chinnappa P, Taguba L, Arciaga R, Faiman C, Siperstein A, Mehta AE, et al. Detection of thyrotropin-receptor messenger ribonucleic acid (mR A) and thyroglobulin mR A transcripts in peripheral blood of patients with thyroid disease: sensitive and specific mar ers for thyroid cancer. J Clin Endocrinol Metab 2004 89: 370-3709.
53. Elisei R, Vivaldi A, Agate L, Molinaro E, Nencetti C, Grasso L, et al. Low specificity of blood thyroglobulin messenger ribonucleic acid assay prevents its use in the follow-up of differentiated thyroid cancer patients. J Clin Endocrinol Metab 2004 89: 33-39.
54. Kaufmann S, Schmutzler C, Schomburg L, Korber C, Luster M, Rendl J, et al. Real time RT-PCR analysis of thyroglobulin mR A in peripheral blood in patients with congenital athyreosis and with differentiated thyroid carcinoma after stimulation with recombinanthumanthyrotropin. EndocrRegul 2004 38: 41-49.
55. Li D, Butt A, Clarke S, Swaminathana R. Real-time quantitative PCR measurement of thyroglobulin mRNA in periph eral blood of thyroid cancer patients and healthy subjects. Ann N Y Acad Sci 2004; 1022: 147-151.
56. Karavitaki N, Lembessis P, Tzanela M, Vlassopoulou V, Thalassinos N, Koutsilieris M. Molecular staging using qualitative RT-PCR analysis detecting thyreoglobulin mRNA in the peripheral blood of patients with differentiated thyroid cancer after therapy. AnticancerRes 2005; 25: 3135-3142.
57. Amakawa M, Kato R, Kameko F, Maruyama M, Tajiri J. Thyroglobulin mRNA expression in peripheral blood lymphocytes of healthy subjects and patients with thyroid disease. Clin ChimActa 2008; 390: 97-103.
58. Lombardi CP, Bossola M, Princi P, Boscherini M, La Torre G, Raffaelli M, et al. Circulating thyroglobulin mRNA does not predict early and midterm recurrences in patients undergoing thyroidectomy for cancer. Am J Surg 2008; 196: 326-332.
59. Boldarine VT, Maciel RM, Guimaraes GS, Nakabashi CC, Camacho CP, et al. Development of a sensitive and specific quantitative reverse transcription-polymerase chain reaction assay for blood thyroglobulin messenger ribonucleic acid in the follow-up of patients with differentiated thyroid carcinoma. J Clin Endocrinol Metab 2010; 95: 1726-1733.
60. Torosian L, Manrique G, Alvarez B, Lago G, Roca R, Belzarena C. Blood thyroglobulin and TSH receptor mRNA detection by RT-PCR in the follow-up of differentiated thyroid cancer patients. Rev Esp Med Nucl 2010; 29: 109-113.
61. Novosel T, Ritter HE, Gupta M, Harvey A, Mitchell J, Berber E, et al. Detection of circulating thyroid cancer cells in patients with thyroid microcarcinomas. Surgery 2009; 146: 1081-1089.
62. Wagner K, Arciaga R, Siperstein A, Milas M, Warshawsky I, Sethu S, et al. Thyrotropin receptor/thyroglobulin messenger ribonucleic acid in peripheral blood and fine-needle aspiration cytology: diagnostic synergy for detecting thyroid cancer. J Clin Endocrinol Metab 2005; 90:1921-1924.
63. Chia SY, Milas M, Reddy SK, Siperstein A, Skugor M, Brainard J, et al. Thyroid-stimulating hormone receptor messenger ribonucleic acid measurement in blood as a marker for circulating thyroid cancer cells and its role in the preoperative diagnosis of thyroid cancer. J Clin Endocrinol Metab 2007; 92: 468-475.
64. Milas M, Shin J, Gupta M, Novosel T, Nasr C, Brainard J, et al. Circulating thyrotropin receptor mRNA as a novel marker of thyroid cancer: clinical applications learned from 1758 samples. Ann Surg 2010; 252: 643-651.
65. Milas M, Barbosa GF, Mitchell J, Berber E, Siperstein A, Gupta M. Effectiveness of peripheral thyrotropin receptor mRNA in follow-up of differentiated thyroid cancer. Ann Surg Oncol 2009; 16: 473-480.
66. Hesse E, Musholt PB, Potter E, Petrich T, Wehmeier M, von Wasielewski R, et al. Oncofoetal fibronectin-a tumour-specific marker in detecting minimal residual disease in differentiated thyroid carcinoma. BrJ Cancer2005; 93: 565-570.
67. Wehmeier M, Petrich T, Brand K, Lichtinghagen R, Hesse E. Onco F et al. Fibronectin mRNA is highly abundant in the blood of patients with papillary thyroid carcinoma and correlates with high-serum thyroid-stimulating hormone levels. Thyroid 2010; 20: 607-613.
68. Sritara C, Charoenphun P, Ponglikitmongkol M, Musikarat S, Utamakul C, Chokesuwattanasakul P, et al. Serum oncofetal fibronectin (onfFN) mRNA in differentiated thyroid carcinoma (DTC): large overlap between disease-free and metastatic patients. Asian Pac J Cancer Prev 2012; 13: 4203-4208.
69. Vendittelli F, Raffaelli M, Fadda G, Carelli-Alinovi C, Paolillo C, Bellantone R, et al. Blood presence of circulating oncofetal fibronectin mR A, by RT-PCR, does not represent a useful specific mar er for the management and follow-up of thyroid cancer patients. Clin Chem Lab Med 2012 50: 715-720.
70. Romei C, Elisei R. RET/PTC translocations and clinico-pathological features in human papillary thyroid carcinoma. Front Endocrinol (Lausanne) 2012; 3: 54.
71. laczkowski KA, Reddi HV, Grebe SK, Eberhardt NL, Mclver B. The role of the PAX8/PPARgamma fusion oncogene in thyroid cancer. PPAR Res 2008; 2008:672829.
72. Fernandez-Medarde A, Santos E. Ras in cancer and developmental diseases. Genes Cancer 2011; 2: 344-358.
73. Xing M. BRAF mutation in thyroid cancer. EndocrRelat Cancer 2005; 12: 245-262.
74. Nikiforov YE, Nikiforova MN. Molecular genetics and diagnosis ofthyroid cancer. Nature RevEndocrinol 2011; 7: 569-580.
75. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417: 949-954.
76. Greenman C, Stephens P, Smith R, Dalgliesh GL, Hunter C, Bignell G, et al. Patterns of somatic mutation in human cancer genomes. Nature 2007; 446: 153-158.
77. Vdovichenko KK, Markova SI, Belokhvostov AS. Mutant form of BRAF gene in blood plasma of cancer patients. Ann N Y Acad Sci 2004; 1022: 228-231.
78. Cradic KW, Milosevic D, Rosenberg AM, Erickson LA, Mclver B, Grebe SK. Mutant BRAF(T1799A) can be detected in the blood of papillary thyroid carcinoma patients and correlates with disease status. J Clin EndocrinolMetab 2009; 94: 5001-5009.
79. Chuang TCY, Chuang AYC, Poeta L, Koch WM, Califano JA, Tufano RP. Detectable BRAF mutation in serum DNA samples from patients with papillary thyroid carcinomas. Head Neck 2010; 32: 229-234.
80. Kwak JY, Jeong JJ, Kang SW, Park S, Choi JR, Park SJ, et al. Study of peripheral BRAF(V600E) mutation as a possible novel marker for papillary thyroid carcinomas. Head Neck 2012; doi: 10.1002/hed.23195.
81. Pupilli C, Pinzani P, Salvianti F, Fibbi B, Rossi M, Petrone L, et al. Circulating BRAFV600E in the diagnosis and follow-up of differentiated papillary thyroid carcinoma. J Clin Endocrinol Metab 2013; 98: 3359-3365.
82. Marquet PY, Daver A, Sapin R, Bridgi B, Muratet JP, Hartmann DJ, et al. Highly sensitive immunoradiometric assay for serum thyroglobulin with minimal interference from autoantibodies. Clin Chem 1996; 42: 258-262.
83. Dai J, Dent W, Atkinson JW, Cox JG, Dembinski TC. Comparison of three immunoassay kits for serum thyroglobulin in patients with thyroid cancer. Clin Biochem 1996; 29: 461-465.
84. Hoofnagle AN, Becker JO, Wener MH, Heinecke JW. Quantification of thyroglobulin, a low-abundance serum protein, by immunoaffinity peptide enrichment and tandem mass spectrometry. Clin Chem 2008; 54: 1796-1804.
85. Kushnir MM, Rockwood AL, Roberts WL, Abraham D, Hoofnagle AN, Meikle AW. Measurement of thyroglobulin by liquid chromatography-tandem mass spectrometry in serum and plasma in the presence of antithyroglobulin autoantibodies. Clin Chem 2013; 59: 982-990.
86. Clarke NJ, Zhang Y, Reitz RE. A novel mass spectrometry-based assay for the accurate measurement of thyroglobulin from patient samples containing antithyroglobulin autoantibodies. J Investig Med 2012; 60: 1157-1163.
87. Kosaka N, Iguchi H, Ochiya T. Circulating microRNA in body fluid: a new potential biomarker for cancer diagnosis and prognosis. Cancer Sci 2010; 101: 2087-2092.
88. Hilton C, Karpe F. Circulating microRNAs: what is their relevance? Clin Chem 2013; 59: 729-731.
89. Allegra A, Alonci A, Campo S, Penna G, Petrungaro A, Gerace D, et al. Circulating microRNAs: new biomarkers in diagn osis, prognosis and treatment of cancer. Int J Oncol 2012; 41:1897-1912
90. Zen K, Zhang CY. Circulating microRNAs: a novel class of biomarkers to diagnose and monitor human cancers. Med Res Rev 2012; 32: 326-348.
91. McDonald JS, Milosevic D, Reddi HV, Grebe SK, Algeciras-Schimnich A. Analysis of circulating microRNA: preanalytical and analytical challenges. Clin Chem 2011; 57: 833-840.
92. Becker N, Lockwood CM. Pre-analytical variables in miRNA analysis. Clin Biochem 2013; 46: 861-868.
93. Dey M, Sharma S, Aggarwal S. Prenatal screening methods for aneuploidies. N Am J Med Sci 2013; 5: 182-190.
94. Banerjee M, Misra D. F et al. Nucleic acids in maternal circulation: a genetic resource for noninvasive prenatal diagnosis. ISRN Genetics 2013; 2013: Article ID 961293, 10 pages.
95. Palomaki GE, Kloza EM, Lambert-Messerlian GM, Haddow JE, Neveux LM, Ehrich M, et al. DNA sequencing of maternal plasma to detect Down syndrome: An international clinical validation study. Genet Med 2011; 13: 913-920.
96. Sehnert AJ, Rhees B, Comstock D, de Feo E, Heilek G, Burke J, Rava RP 2011 Optimal detection of fetal chromosomal abnormalities by massively parallel DNA sequencing of cell-free fetal DNA from maternal blood. Clin Chem 57:1042-1049.
97. Monaco F, Grimaldi S, Dominici R, Robbins J. Defective thyroglobulin synthesis in an experimental rat thyroid tumor: iodination and thyroid hormone synthesis in isolated tumor thyroglobulin. Endocrinology 1975; 97: 347-351.
98. Druetta L, Croizet K, Bornet H, Rousset B. Analyses of the molecular forms of serum thyroglobulin from patients with Graves' disease, subacute thyroiditis or differentiated thyroid cancer by velocity sedimentation on sucrose gradient and Western blot. Eur J Endocrinol 1998; 139: 498-507.
99. Druetta L, Bornet H, Sassolas G, Rousset B. Identification of thyroid hormone residues on serum thyroglobulin: a clue to the source of circulating thyroglobulin in thyroid diseases. Eur J Endocrinol 1999; 140: 457-467.
100. Gerard A-C, Daumerie C, Mestdagh C, Gohy S, de Burbure C, Costagliola S, et al. Correlation between the loss of thyroglobulin iodination and the expression of thyroid-specific proteins involved in iodine metabolism in thyroid carcinomas. J Clin Endocrinol Metab 2003; 88: 4977-4983.
101. Emoto N, Kunii YK, Ashizawa M, Oikawa S, Shimizu K, Shimonaka M, etal. Reduced sulfation of chondroitin sulfate in thyroglobulin derived from human papillary thyroid carcinomas. CancerSci 2007; 98:1577-1581.
102. Shimizu K, Nakamura K, Kobatake S, Satomura S, Maruyama M, Kameko F, et al. The clinical utility of Lens culinaris agglutinin-reactive thyroglobulin ratio in serum for distinguishing benign from malignant conditions of the thyroid. Clin Chim Acta 2007; 379: 101-104.